Cumulative incidence of clinically significant events after anti–PD-1 administration. (A) Time from anti–PD-1 administration to development of treatment-emergent grade II-IV and grade III-IV aGVHD. (B) Time from anti–PD-1 administration to treatment-emergent moderate/severe and severe cGVHD. (C) Time from anti–PD-1 administration to lymphoma progression. (D) Time from anti–PD-1 administration to death. aGVHD and cGVHD stage/grade and responses were scored according to Consensus and NIH criteria, respectively.